This product contains:CJC-1295 with DAC, CJC-1295 without DAC
Other names:CJC-1295, CJC-1295 no DAC, CJC-1295 without DAC,CJC-1295 (DAC), CJC 1295 with DAC, CJC-1295 DAC; CJC-1295+DAC, CIC- 1295 Acetate, Mod GRF (1-29), Modified GRF 1-29, DAC:GRF, GHRH derivative;Modified GRF (1-29) with Drug Affinity Complex, CJC-1295 Drug Affinity Complex, CJC-1295 with Drug Affinity Complex Peptide, (DAC) Peptide, GRF (1-29) with Drug Affinity Complex, CJC-1295 DAC Peptide
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to elevate plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). CJC-1295 DAC is a specially designed peptide known as the best hGH secretagogue. DAC (Drug Affinity Complex) prolongs half-life partially by binding to serum albumin and protects CJC-1295 DAC peptide from degradation. The peptide is intended to treat visceral fat deposition in obese AIDS patients, as increased levels of exogenous HGH are thought to increase lipolysis (fat loss). In meanwhile, CJC-1295 has proven to help with fat loss and increase cellular repair and regeneration.
◐ Production capacity: Provide customization
◐ Large Factory Professional Manufacturers & Factory
◐ Production Carried OUT Under CGMP Regulation and Trackable
◐ ISO9001 & ISO14000
Get a Bulk quotation
If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.
Coa & Ms
Where to buy?
|Molecular Weight:||3367.954 g/mol|
|Synonyms:||CJC-1295; CJC 1295 with DAC; CJC-1295 DAC; CJC-1295+DAC; CJC-1295 NO DAC;|
Coa & Ms
Where to buy?
CJC-1295 with DAC, CJC-1295 without DAC Peptide dosage calculator
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. Epub 2005 Dec 13.
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009 Dec;19(6):471-7. doi: 10.1016/j.ghir.2009.03.001. Epub 2009 Apr 21.
Jump up to:a b c d e f Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (March 2006). “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults”. The Journal of Clinical Endocrinology and Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. PMID 16352683.
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. (July 2005). “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog”. Endocrinology. 146 (7): 3052–8. doi:10.1210/en.2004-1286. PMID 15817669.
Jump up to:a b c Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R (December 2006). “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse”. American Journal of Physiology. Endocrinology and Metabolism. 291 (6): E1290-4. doi:10.1152/ajpendo.00201.2006. PMID 16822960.
Ionescu M, Frohman LA (December 2006). “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog”. The Journal of Clinical Endocrinology and Metabolism. 91 (12): 4792–7. doi:10.1210/jc.2006-1702. PMID 17018654.
“Current Research Findings Regarding CJC-1295”. Neo Scientific. 2 June 2015. Archived from the original on 7 April 2019. Retrieved 3 August 2015. The reason why CJC1295 possesses the ability to lengthen the half-life within the active agent has to do with the scientific process known as bioconjugation. This technology, which is relatively new in nature, is defined by its ability to take a reactive group and bond it to a peptide (Aslam and Dent). This attachment causes a reaction with a nucleophilic unit; a typically partially molecule that is found within the bloodstream of an animal test subject. This reaction in turn causes a more stable bond to occur. This specific peptide has an especially high attraction to albumin, a globular protein that is soluble in water. This affinity prohibits natural degradation, which in turn increases the peptide’s half-life (Hermanson). Additionally, clinical research performed on animal test subjects has thus far shown that there have been no signs of DPP-IV degradation present when CJC-1295 was introduced (Gonzalez, US Peptide Articles).
Henninge J, Pepaj M, Hullstein I, Hemmersbach P (2010). “Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation”. Drug Testing and Analysis. 2 (11–12): 647–50. doi:10.1002/dta.233. PMID 21204297
Alba, M, Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori,R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
Van Hout, M. C., & Hearne, E. (2016). Netnography of female use of the synthetic growth hormone CJC- 1295: pulses and potions. Substance Use & Misuse, 51(), 73-84.
National Center for Biotechnology Information. “PubChem Compound Summary for CID 91976842, CJC1295 Without DAC” PubChem.
Timms M, Ganio K, Steel R.”A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS”Drug Test Anal. 2019 Aug;11(8):1248-1257. doi: 10.1002/dta.2599. Epub 2019 May 8.PMID: 30938069.
Kwok WH, Ho EN, Lau MY, Leung GN, Wong AS, Wan TS.” Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry”Anal Bioanal Chem. 2013 Mar;405(8):2595-606. doi: 10.1007/s00216-012-6697-9. Epub 2013 Jan 15.PMID: 23318763.
Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V.”Advances in the detection of growth hormone releasing hormone synthetic analogs” Drug Test Anal. 2021 Nov;13(11-12):1871-1887. doi: 10.1002/dta.3183. Epub 2021 Nov 7.PMID: 34665524.
Pineau T, Schopfer A, Grossrieder L”The study of doping market: How to produce intelligence from Internet forums”Forensic Sci Int. 2016 Nov;268:103-115. doi: 10.1016/j.forsciint.2016.09.017. Epub 2016 Sep 27. PMID: 27710891.
Growth hormone-releasing hormone (GHRH) has undergone several modifications to create analogs that retain certain effects while eliminating others. Among these modifications is CJC-1295, which encompasses the first 29 amino acids of GHRH. CJC-1295, technically a maleimido derivative of hGRF(1-29), was developed to enhance solubility as a growth hormone secretagogue and facilitate large-scale production while maintaining the physiological actions of GHRH.
CJC-1295 Versus CJC-1295 DAC
CJC-1295 is a derivative of the initial 29 amino acids of growth hormone-releasing hormone (GHRH), making it structurally akin to other GHRH analogs such as Sermorelin. Although it bears the greatest resemblance to modified GRF (1-29), the two peptides are not identical. Much confusion arises due to the peptide’s similarities with others and the inclusion of a supplementary chemical compound known as the drug affinity complex (DAC) in the original formulation of CJC-1295.
Half-life of CJC-1295-DAC compared to standard growth hormone releasing factor (GRF)
Authoritative source：Oxford Academic
Initially, ConjuChem Biotechnologies, the creator of DAC, labeled the peptide with DAC as CJC-1295. However, this caused confusion as the peptide was also available without DAC. To alleviate this confusion, the version of CJC-1295 that includes DAC is now referred to as CJC-1295-DAC, while the version without DAC is simply called CJC-1295 or CJC-1295-no DAC.
Sequence: Tyr-D-Ala-Asp-Ala-le-Phe- Th-GIn-Ser-Ty-Arg-Lys-Val-Leu-Ala-GIn-Leu-Se-Ala-Arg-Lys-Leu-Leu-GIn-Asp-lle-Leu-Ser-Arg
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.954 g/mol
PubChem CID: 56841945
Sequence: Ty-D-Ala-Asp-Aa-l-Phe Th-GIn-Ser-TyT-Arg-Lys-Val-Leu-Ala-GIn-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gin-Asp-lle-Leu-Ser-Arg-Lys-DAC
Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol
PubChem CID: 91976842
CJC-1295 and Growth Hormone Release
Being a derivative of GHRH, it is expected that CJC-1295 stimulates the secretion of GH. Research indicates that a single dose of CJC-1295 can increase GH levels in mice by 2-10 times. The highest GH levels are typically observed around 2 hours after administration, and the effects can last for approximately six days. Unlike other GH secretagogues, CJC-1295 maintains the natural physiological pattern of GH release. This means that the regular circadian peaks and troughs in GH secretion are preserved, making CJC-1295 a physiologically relevant growth hormone-releasing factor.
Preserving physiologic release of GH even while influencing the maximum concentration of the hormone in the bloodstream is critical to ensuring enhanced effects without increased side effects. In particular, CJC-1295 has been demonstrated to preserve growth hormone’s physiologic effects on hyperplasia, hypertrophy, bone density, blood sugar, fat metabolism, protein synthesis, and myocardial (heart cell) function.
CJC-1295 and Growth
Studies conducted on mice lacking normal GHRH physiology have demonstrated that CJC-1295 maintains the regular release of GH. This characteristic of the peptide holds potential for therapeutic applications in addressing abnormal growth in various mammalian species, including humans. Preserving the natural pulsatile release of GH is crucial in ensuring the appropriate secretion of downstream hormones, such as insulin-like growth factor-2 (IGF-1).
CJC-1295 and Infertility
Research conducted in the early 1990s suggests that CJC-1295 and other GRF analogues could potentially be beneficial in promoting ovulation in infertile female patients. It has been well-established that ovulation is dependent on IGF-1 and likely influenced by GH release and cycling. Animal studies focusing on superovulation have further supported these theories by demonstrating significant increases in both GH and IGF-1 levels during the ovulation period. Moreover, these studies indicate that the administration of exogenous GH secretagogues, such as CJC-1295, is sufficient to induce proper ovulation. There is also speculation that CJC-1295 and similar analogues might have potential applications in male infertility by aiding in the regulation of sperm production, although this hypothesis has yet to be tested.
CJC-1295 is a growth hormone secretagogue specifically designed to have a prolonged plasma half-life and to preserve the natural patterns of the GH axis. It has proven successful in achieving these goals. While the molecule initially generated limited interest in research settings due to the emergence of similar compounds and its proprietary nature, the ability to manufacture CJC-1295 more freely is likely to reignite curiosity in its properties, especially regarding its potential applications in addressing the challenging issue of human infertility.
In studies conducted on mice, CJC-1295 has demonstrated moderate side effects, low oral bioavailability, and excellent subcutaneous bioavailability. However, it is important to note that the dosage per kilogram used in mice is not directly applicable to humans. Consequently, the sale of CJC-1295 by Peptide Sciences is strictly limited to educational and scientific research purposes and is not intended for human consumption. Therefore, purchasing CJC-1295 is only appropriate for licensed researchers. 
 Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions [Tandfonline.com]
 M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]
 M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]
 A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no. 9, pp. 1228–1232, Oct. 1991. [PubMed]
 Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]
scientific journal paper author:
Pharmacologie/toxicologie, laboratoire MassSpecLab, université Versailles-Saint-Quentin-en-Yvelines, Inserm U-1173, CHU Garches, 71180 Montigny-le-Bretonneux, France.
Department of Biological Sciences, Ohio University, Athens, Ohio 45701, United States.
Department of Neuroendocrinology, Medical Center of Postgraduate Education, Warsaw, Poland.
Department of Physiology, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain.
Department of Clinical Physiology, Section of Clinical Neurophysiology, Karolinska Institute, Huddinge, Sweden
In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.